70396-18-8

Usage

Uses

Used in Pharmaceutical Industry:
L-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-L-valylis used as a cleavable ADC linker for targeted drug delivery. Its stability in human plasma and efficient cleavage by lysosomal proteolytic enzymes allow for the precise delivery of therapeutic agents to cancer cells, minimizing damage to healthy cells and reducing side effects.
Additionally, the Boc group's ability to be deprotected under mild acidic conditions provides further control over the drug release, enhancing the therapeutic efficacy of ADCs.

Upstream product

• 3392-12-9 Boc-Val-ONSu 
• 56-41-7 L-alanin 
• 13734-41-3 t-Boc-L-valine 
• 95499-91-5 Boc-Val-NHNHPh 
• 226543-65-3 Boc-Val-Ala-NHNHPh 
• 130380-44-8 N-tert-Butyloxycarbonyl-L-valyl-L-alanin-heptylester 
• 15275-65-7 (S)-methyl 2-((S)-2-((tert-butoxycarbonyl)amino)-3-methylbutanamido)propanoate 

Downstream Products

• 197781-20-7 Boc-Val-Ala-Phe-OMe 
• 1884578-00-0 tert-butyl ((S)-3-methyl-1-(((S)-1-((4-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenyl)amino)-1-oxopropan-2-yl)amino)-1-oxobutan-2-yl)carbamate 

Relevant academic research and scientific papers

CHARACTERIZATION OF A CHIRAL TRIPEPTIDE STATIONARY PHASE FOR THE LIQUID CHROMATOGRAPHIC SEPARATION OF CHIRAL DIPEPTIDES.

A tripeptide-bonded stationary phase was synthesized by bonding the tripeptide, L-Val-L-Ala-L-Pro, to a reactive silane bonded to silica gel. The retention behavior of several isomeric dipeptides was examined as a function of pH and buffer composition. Although retention behaviors were similar to those reported for the nominally same tripeptide phase prepared in another way, the data indicated that the phases were significantly different. In addition, for the new phase at pH 7. 4, a buffer effect was found in which retentions decreased on going from a phosphate-citrate-chloride (McIlvaine) to phosphate buffer alone, to citrate alone, and to pyrophosphate.

ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS

Conjugate of a binder having formula (AA) wherein AB stands for a binder, Z' stands for a linker, D stands for an active component which is a NAMPT inhibitor and its use as pharmaceuticals.

Introducing sequential aza-amino acids units induces repeated β-turns and helical conformations in peptides

A major current issue in medicinal chemistry is the design of small peptide analogues resistant to proteolysis and able to adopt preferential conformations, while preserving the selectivity and efficiency of natural peptides. Whereas the introduction of one aza-Gly in peptides has proven numerous biological and structural interest, the conformational effect of sequential aza-Gly or aza-amino acids bearing side chains has not been investigated. In this work, experimental NMR and X-ray data together with in silico conformational studies reveal that the introduction of two consecutive aza-amino acids in pseudotripeptides induces the formation of stable hydrogen-bonded β-turn structures. Notably, this stabilization effect relies on the presence of side chains on aza-amino acids, as more flexible conformations are observed with aza-Gly residues. Remarkably, a longer aza/aza/α/aza/aza/α pseudohexapeptide containing substituted aza-amino acids adopts repeated β-turns conformations which interconvert with a fully helical structure mimicking a 310 helix.

CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES

The invention relates to benzodiazepine derivatives with antiproliferative activity and more specifically to benzodiazepine compounds of formulae (I), (II), (TI) and (T2). The invention also provides conjugates of the benzodiazepine compounds linked to a

The antibody-drug conjugate hemiasterlin derivatives and their pharmaceutically (by machine translation)

[Problem] to give one specific target cell cytotoxic, normal cells to the cytotoxic is suppressed, the antibody-drug conjugate medicine hemiasterlin derivatives. (2) Formula [a]:[In the formula, mAb antibody expressed, q is 1 - 8 represents an integer of, h are 1 - 5 represents an integer of, g is an alanine residue (Ala) to represent, g is 1 - 4 represents an integer of, Y is a single bond or a formula (Y-a 1) is represented by the group, Z is formula (Z-a 1), equation (Z-a 2), equation (Z-a 3), formula (Z-a 4), formula (Z-a 5), type (Z-a 6), formula (Za-a 1), equation (Za-in 2), equation (Za-a 3), formula (Za-a 4), formula (Za-a 5), type (Za d 6), formula (Za-a 7), type (Za-in 8), or a group represented by formula (Za-a 10) (Za-a 9) formula a] is expressed by, antibody-drug conjugate or its pharmaceutically acceptable salt containing a drug. [Drawing] no (by machine translation)

Tripeptide based super-organogelators: Structure and function

A novel series of tripeptide-based low molecular weight super-organogelators were synthesized and characterized. Four tripeptides with diverse steric crowding at the central amino acid residue were studied. From this series, only sterically less hindered

MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES

Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.

TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES

Compounds and compositions are disclosed in which a quaternized drug unit is linked to a targeting ligand unit from which a tertiary amine-containing drug is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease using the compounds and compositions of the invention are also disclosed.

MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES

Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.

Oxidation of peptides by methyl(trifluoromethyl)dioxirane: The protecting group matters

Representative Boc-protected and acetyl-protected peptide methyl esters bearing alkyl side chains undergo effective oxidation using methyl(trifluoromethyl)dioxirane (1b) under mild conditions. We observe a protecting group dependency in the chemoselectivity displayed by the dioxirane 1b. N-Hydroxylation occurs in the case of the Boc-protected peptides, and side chain hydroxylation takes place in the case of acetyl-protected peptides. Both are attractive transformations since they yield derivatized peptides that serve as valuable synthons.